Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)

This publication has 31 references indexed in Scilit:

• Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality
  American Heart Journal, 2003
• Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation: SPORTIF ii: a dose-guiding, tolerability, and safety study
  Journal of the American College of Cardiology, 2003
• Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions
  Clinical Pharmacokinetics, 2003
• Influence of Age on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor
  Clinical Pharmacokinetics, 2003
• Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications
  Published by Oxford University Press (OUP) ,2001
• Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials
  Archives of internal medicine (1960), 1994
• Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study*1
  The Lancet, 1994
• Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
  The Lancet, 1993
• Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.
  Stroke, 1991
• Embolic complications in paroxysmal atrial fibrillation.
  Stroke, 1986